Efficacy of transesophageal echocardiography for reviewing left atrial thrombosis and influence fac-tor analysis in patients with non-valvular atrial fibrillation
Efficacy of transesophageal echocardiography for reviewing left atrial thrombosis and influence fac-tor analysis in patients with non-valvular atrial fibrillation
Objective To investigate the efficacy of transesophageal echocardiography(TEE)for reviewing left atrial thrombosis,and analyze the influence factors for thrombosis and spontaneous echo contrast(SEC)in patients with non-valvular atrial fibrillation(NVAF).Methods NVAF patients(n=150)received TEE were chosen from the Second People's Hospital of Liaocheng City of Shandong Province from Jan.2019 to Jan.2022.The patients were divided,according to occurrence of left atrial thrombosis or SEC,into thrombus group(n=32)and non-thrombus group(n=118).The general material and parameters of cardiac uhrasonographywere collected in 2 groups.The risk factors for left atrial thrombosis were analyzed by using single-factor and multi-factor Logistics regression analysis in NVAF patients.The predictive value of receiver operating characteristic(ROC)curveto left atrial thrombosis was analyzed in NVAF patients.Results The levels of left atrial anteroposterior diameter(LAAPD)was higher,and levels of left atrial appendage peak flow emptying velocity(LAAV),left ventricular ejection fraction(LVEF)and global left atrial longitudinal strain(GLALS)were lower in thrombus group than those in non-thrombus group(P＜0.05).The results of binary Logistics regression analysis showed that LAAPD,LAAV,LVEF and GLALS were influence factors for left atrial thrombosis(P＜0.05).The results of ROC curve analysis showed that AUC of LAAPD,LAAV,LVEF,GLALS and combined prediction was,respectively,0.899,0.892,0.816,0.822 and 0.986 in predicting left atrial thrombosis(P＜0.05).Conclusion LAAPD,LAAV,LVEF and GLALS detected by TEE are influence factors and have some predictive value to left atrial thrombosis,especially the combination prediction is the most effective in NVAF patients.
维普
万方数据